project id: TCGA-BLCA; case submitter id: TCGA-DK-A3IT; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.4; rna integrity number: 7.0; age at index: 62; days to birth: -22786; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1949; age at diagnosis: 22786; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 648.0; icd 10 code: C67.2; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lateral wall of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Lateral wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 145; days to sample procurement: 0; initial weight: 240.0; portion submitter id: TCGA-DK-A3IT-01A-31; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 40.0; percent stromal cells: 0.0; percent tumor cells: 60.0; percent tumor nuclei: 70.0;